Samsung Biologics: 타법인주식및출자증권취득결정(종속회사의주요경영사항)
AI reading
★★★ Bullish · M&A/investment
Strengthening business competitiveness through acquisition of peptide CDMO company
Key figures: 취득금액 2,706,163,546,103원·자산총액대비 24.47%
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Samsung Biologics
- 09.10 ★★★ Signed pharmaceutical contract manufacturing agreement with European pharmaceutical company
- 09.10 ★★ [Correction] Execution of Supply Contract
- 08.28 ★★ Decision on large-scale rights offering and public offering for facility investment and acquisition of securities of other corporations
- 08.28 ★★ [Amended] Material report on the decision to acquire shares and equity securities of other corporations
For information only. Not investment advice.